January 2026, Vol 16, No 1
For oncology patients, the emergency department is often the wrong place at the wrong time. Read More ›
By Rifeta Kajdić-Hodžić, CHPM; Christie Mangir, MS; Allison Harvey, MPH, CHES; Meredith Doherty, PhD, LCSW; Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN; Rebecca Kirch, JD; Angie Santiago, BBA, CRCS, FACCC; Lori Schneider, FACCC; Elana Plotkin, CMP-HC
This research was presented, in part, as a poster at the 2022 ASCO Quality Care Symposium and online-only as an abstract at the 2023 ASCO Annual Meeting. Read More ›
On November 18, 2025, the FDA approved epcoritamab-bysp (Epkinly) in combination with lenalidomide and rituximab (R2) for relapsed or refractory follicular lymphoma (FL). Read More ›
On November 19, 2025, the FDA granted traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer that progressed after platinum-based chemotherapy. Read More ›
On November 19, 2025, the FDA granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain (TKD)-activating mutations, as identified by an FDA-approved test, who had received prior systemic therapy. Read More ›
On November 21, 2025, the FDA approved pembrolizumab (Keytruda), or pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex), in combination with enfortumab vedotin-ejfv (Padcev), as neoadjuvant therapy followed by adjuvant therapy after cystectomy for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Read More ›
On December 3, 2025, the FDA granted traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a covalent BTK inhibitor. Read More ›
As we approach 2026, the landscape of physician reimbursement and care delivery will not be business as usual. Between new legislation, major updates to the Medicare Physician Fee Schedule (PFS), and rapid advances in artificial intelligence (AI) and care technology, healthcare delivery is entering a period of significant transition. Read More ›